JP2018505882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505882A5 JP2018505882A5 JP2017541030A JP2017541030A JP2018505882A5 JP 2018505882 A5 JP2018505882 A5 JP 2018505882A5 JP 2017541030 A JP2017541030 A JP 2017541030A JP 2017541030 A JP2017541030 A JP 2017541030A JP 2018505882 A5 JP2018505882 A5 JP 2018505882A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pasi
- composition according
- patient
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 102000004965 antibodies Human genes 0.000 claims 9
- 108090001123 antibodies Proteins 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 201000004681 psoriasis Diseases 0.000 claims 4
- 102100014203 IL23A Human genes 0.000 claims 2
- 101700036088 IL23A Proteins 0.000 claims 2
- 230000001684 chronic Effects 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
Claims (15)
- 配列番号１８のアミノ酸配列を含む軽鎖及び配列番号１９のアミノ酸配列を含む重鎖を含む抗ＩＬ−２３Ａ抗体を含み、１５０ｍｇの抗ＩＬ−２３Ａ抗体を患者に投与するための、乾癬を処置するための医薬組成物。
- 中等症から重症の慢性尋常性乾癬を処置するための、請求項１記載の医薬組成物。
- 前記の抗ＩＬ−２３Ａ抗体が皮下投与によって投与される、請求項１又は２記載の医薬組成物。
- 患者がPasoriasis Area and Severity Index（ＰＡＳＩ）スコア５０（ＰＡＳＩ ５０）を達成する、請求項１〜３のいずれか一項記載の医薬組成物。
- 患者がＰＡＳＩスコア７５（ＰＡＳＩ ７５）を達成する、請求項１〜４のいずれか一項記載の医薬組成物。
- 患者がＰＡＳＩスコア９０（ＰＡＳＩ ９０）を達成する、請求項１〜５のいずれか一項記載の医薬組成物。
- 患者がＰＡＳＩスコア１００（ＰＡＳＩ １００）を達成する、請求項１〜６のいずれか一項記載の医薬組成物。
- 配列番号１８のアミノ酸配列を含む軽鎖及び配列番号１９のアミノ酸配列を含む重鎖を含む、抗ＩＬ−２３Ａ抗体を含む、乾癬を処置するための医薬組成物であって、
ａ）初回用量として１５０ｍｇの前記の抗ＩＬ−２３Ａ抗体を患者に投与する工程；
ｂ）前記の初回用量が投与された４週間後に、２回目の用量として１５０ｍｇの前記の抗ＩＬ−２３Ａ抗体を患者に投与する工程；及び
ｃ）前記の２回目の用量が投与された１２週間後に、１回目の維持用量として１５０ｍｇの抗ＩＬ−２３Ａ抗体を患者に投与する工程
を含む方法により患者に投与される、医薬組成物。 - 前記方法は、さらに
前記の１回目の維持用量が投与された後に、１２週間毎に、維持用量として１５０ｍｇの前記抗ＩＬ−２３Ａ抗体を投与する工程
を含む、請求項８記載の医薬組成物。 - 前記の方法が、中等症から重症の慢性尋常性乾癬を処置するためのものである、請求項８又は９記載の医薬組成物。
- 前記の抗ＩＬ−２３Ａ抗体が皮下投与によって投与される、請求項８〜１０のいずれか一項記載の医薬組成物。
- 患者がＰＡＳＩスコア５０（ＰＡＳＩ ５０）を達成する、請求項８〜１１のいずれか一項記載の医薬組成物。
- 患者がＰＡＳＩスコア７５（ＰＡＳＩ ７５）を達成する、請求項８〜１２のいずれか一項記載の医薬組成物。
- 患者がＰＡＳＩスコア９０（ＰＡＳＩ ９０）を達成する、請求項８〜１３のいずれか一項記載の医薬組成物。
- 患者がＰＡＳＩスコア１００（ＰＡＳＩ １００）を達成する、請求項８〜１４のいずれか一項記載の医薬組成物。
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562111731P | 2015-02-04 | 2015-02-04 | |
| US62/111,731 | 2015-02-04 | ||
| US201562130876P | 2015-03-10 | 2015-03-10 | |
| US62/130,876 | 2015-03-10 | ||
| US201562135335P | 2015-03-19 | 2015-03-19 | |
| US62/135,335 | 2015-03-19 | ||
| US201562145764P | 2015-04-10 | 2015-04-10 | |
| US62/145,764 | 2015-04-10 | ||
| US201562204520P | 2015-08-13 | 2015-08-13 | |
| US62/204,520 | 2015-08-13 | ||
| US201562235631P | 2015-10-01 | 2015-10-01 | |
| US62/235,631 | 2015-10-01 | ||
| PCT/US2016/016061 WO2016126638A1 (en) | 2015-02-04 | 2016-02-02 | Methods of treating inflammatory diseases |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020078177A Division JP7044824B2 (ja) | 2015-02-04 | 2020-04-27 | 炎症性疾患の処置法 |
| JP2020078179A Division JP7042298B2 (ja) | 2015-02-04 | 2020-04-27 | 炎症性疾患の処置法 |
| JP2020078178A Division JP7042297B2 (ja) | 2015-02-04 | 2020-04-27 | 炎症性疾患の処置法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505882A JP2018505882A (ja) | 2018-03-01 |
| JP2018505882A5 true JP2018505882A5 (ja) | 2019-03-14 |
| JP6758304B2 JP6758304B2 (ja) | 2020-09-23 |
Family
ID=55453266
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541030A Active JP6758304B2 (ja) | 2015-02-04 | 2016-02-02 | 炎症性疾患の処置法 |
| JP2020078179A Active JP7042298B2 (ja) | 2015-02-04 | 2020-04-27 | 炎症性疾患の処置法 |
| JP2020078177A Active JP7044824B2 (ja) | 2015-02-04 | 2020-04-27 | 炎症性疾患の処置法 |
| JP2020078178A Active JP7042297B2 (ja) | 2015-02-04 | 2020-04-27 | 炎症性疾患の処置法 |
| JP2022042417A Pending JP2022081644A (ja) | 2015-02-04 | 2022-03-17 | 炎症性疾患の処置法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020078179A Active JP7042298B2 (ja) | 2015-02-04 | 2020-04-27 | 炎症性疾患の処置法 |
| JP2020078177A Active JP7044824B2 (ja) | 2015-02-04 | 2020-04-27 | 炎症性疾患の処置法 |
| JP2020078178A Active JP7042297B2 (ja) | 2015-02-04 | 2020-04-27 | 炎症性疾患の処置法 |
| JP2022042417A Pending JP2022081644A (ja) | 2015-02-04 | 2022-03-17 | 炎症性疾患の処置法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20160222102A1 (ja) |
| EP (1) | EP3253794A1 (ja) |
| JP (5) | JP6758304B2 (ja) |
| KR (1) | KR20170120616A (ja) |
| CN (2) | CN113559258A (ja) |
| AU (2) | AU2016215535B2 (ja) |
| BR (1) | BR112017014684A2 (ja) |
| CA (1) | CA2972995A1 (ja) |
| CL (1) | CL2017001960A1 (ja) |
| EA (1) | EA201791734A1 (ja) |
| IL (2) | IL307578A (ja) |
| MX (3) | MX2017010037A (ja) |
| PH (1) | PH12017501378A1 (ja) |
| SG (2) | SG11201705728RA (ja) |
| WO (1) | WO2016126638A1 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3281954A1 (en) | 2010-11-04 | 2018-02-14 | Boehringer Ingelheim International GmbH | Anti-il-23 antibodies |
| NZ700802A (en) | 2012-05-03 | 2017-06-30 | Boehringer Ingelheim Int | Anti-il-23p19 antibodies |
| WO2016014775A1 (en) | 2014-07-24 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of il-23a related diseases |
| SG10201912591RA (en) | 2014-09-03 | 2020-02-27 | Boehringer Ingelheim Int | Compound targeting il-23a and tnf-alpha and uses thereof |
| EP3253794A1 (en) * | 2015-02-04 | 2017-12-13 | Boehringer Ingelheim International GmbH | Methods of treating inflammatory diseases |
| EP3974451A3 (en) * | 2016-04-15 | 2022-07-06 | Boehringer Ingelheim International GmbH | Methods of treating inflammatory diseases |
| WO2018064436A1 (en) * | 2016-09-30 | 2018-04-05 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-il23 specific antibody |
| CN106778030B (zh) * | 2017-01-10 | 2023-04-07 | 广州和康医疗技术有限公司 | 一种强直性脊柱炎病情监测管理系统及其监测管理方法 |
| MX2021005905A (es) | 2018-11-20 | 2021-06-23 | Janssen Biotech Inc | Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23. |
| CN111378045B (zh) * | 2018-12-28 | 2022-08-02 | 长春金赛药业有限责任公司 | 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 |
| US20210070852A1 (en) * | 2019-09-09 | 2021-03-11 | Boehringer Ingelheim International Gmbh | Anti-IL-23p19 Antibody Formulations |
| WO2023144699A1 (en) * | 2022-01-25 | 2023-08-03 | Sun Pharmaceutical Industries Limited | Methods for treatment of subjects with plaque psoriasis of the scalp |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| LT2452694T (lt) | 2005-06-30 | 2019-02-25 | Janssen Biotech, Inc. | Anti-il-23 antikūnai, kompozicijos, būdai ir panaudojimai |
| US7872102B2 (en) | 2005-08-25 | 2011-01-18 | Eli Lilly And Company | Anti-IL-23 antibodies |
| PT1931710T (pt) * | 2005-08-31 | 2017-03-28 | Merck Sharp & Dohme | Anticorpos anti-il-23 manipulados |
| DK3219328T3 (da) | 2005-12-29 | 2020-07-13 | Janssen Biotech Inc | Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
| ATE554791T1 (de) | 2007-02-23 | 2012-05-15 | Schering Corp | Gentechnisch hergestellte anti-il-23p19- antikörper |
| EP3281954A1 (en) * | 2010-11-04 | 2018-02-14 | Boehringer Ingelheim International GmbH | Anti-il-23 antibodies |
| NZ700802A (en) * | 2012-05-03 | 2017-06-30 | Boehringer Ingelheim Int | Anti-il-23p19 antibodies |
| EP2866833B1 (en) * | 2012-06-27 | 2019-05-15 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
| EA201591581A1 (ru) * | 2013-03-15 | 2016-01-29 | Амген Инк. | Способы лечения псориаза при помощи анти-il-23 антитела |
| EP3253794A1 (en) | 2015-02-04 | 2017-12-13 | Boehringer Ingelheim International GmbH | Methods of treating inflammatory diseases |
| JP7090014B2 (ja) * | 2018-11-07 | 2022-06-23 | 株式会社ミツバ | ロータ、モータ、ブラシレスワイパーモータ及びロータの製造方法 |
-
2016
- 2016-02-02 EP EP16707997.9A patent/EP3253794A1/en active Pending
- 2016-02-02 IL IL307578A patent/IL307578A/en unknown
- 2016-02-02 KR KR1020177024896A patent/KR20170120616A/ko not_active Application Discontinuation
- 2016-02-02 US US15/013,008 patent/US20160222102A1/en active Pending
- 2016-02-02 SG SG11201705728RA patent/SG11201705728RA/en unknown
- 2016-02-02 JP JP2017541030A patent/JP6758304B2/ja active Active
- 2016-02-02 MX MX2017010037A patent/MX2017010037A/es unknown
- 2016-02-02 AU AU2016215535A patent/AU2016215535B2/en active Active
- 2016-02-02 WO PCT/US2016/016061 patent/WO2016126638A1/en active Application Filing
- 2016-02-02 SG SG10202103879YA patent/SG10202103879YA/en unknown
- 2016-02-02 CA CA2972995A patent/CA2972995A1/en active Pending
- 2016-02-02 CN CN202110769475.7A patent/CN113559258A/zh active Pending
- 2016-02-02 BR BR112017014684A patent/BR112017014684A2/pt active Search and Examination
- 2016-02-02 CN CN201680008402.3A patent/CN107206081A/zh active Pending
- 2016-02-02 EA EA201791734A patent/EA201791734A1/ru unknown
-
2017
- 2017-06-22 IL IL253118A patent/IL253118A0/en unknown
- 2017-08-01 CL CL2017001960A patent/CL2017001960A1/es unknown
- 2017-08-01 PH PH12017501378A patent/PH12017501378A1/en unknown
- 2017-08-03 MX MX2022006575A patent/MX2022006575A/es unknown
- 2017-08-03 MX MX2022006573A patent/MX2022006573A/es unknown
-
2020
- 2020-04-27 JP JP2020078179A patent/JP7042298B2/ja active Active
- 2020-04-27 JP JP2020078177A patent/JP7044824B2/ja active Active
- 2020-04-27 JP JP2020078178A patent/JP7042297B2/ja active Active
-
2021
- 2021-12-16 AU AU2021286378A patent/AU2021286378A1/en active Pending
-
2022
- 2022-03-17 JP JP2022042417A patent/JP2022081644A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018505882A5 (ja) | ||
| JP2016528247A5 (ja) | ||
| JP2017503820A5 (ja) | ||
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| RU2016130056A (ru) | Способы лечения кожной инфекции путем введения антагониста il-4r | |
| AR091701A1 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
| JP2017512193A5 (ja) | ||
| JP2015525798A5 (ja) | ||
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| WO2007145941A8 (en) | Administration of anti-cd3 antibodies in the treatment of autoimmune diseases | |
| JP2016529255A5 (ja) | ||
| JP2016503413A5 (ja) | ||
| JP2016530280A5 (ja) | ||
| JP2015517488A5 (ja) | ||
| JP2012518624A5 (ja) | ||
| RU2015136392A (ru) | Композиции и способы, основанные на нейтрализующих антителах, доставляемых интраназально, для улучшенной терапевтической эффективности | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| BR112015010396A2 (pt) | terapia de combinação | |
| JP2017503014A5 (ja) | ||
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2018510132A5 (ja) | ||
| NZ744233A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| WO2016168553A8 (en) | Deuterated obeticholic acid | |
| JP2015522015A5 (ja) |